Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5197266
Max Phase: Preclinical
Molecular Formula: C21H21Cl2N7O
Molecular Weight: 458.35
Associated Items:
ID: ALA5197266
Max Phase: Preclinical
Molecular Formula: C21H21Cl2N7O
Molecular Weight: 458.35
Associated Items:
Canonical SMILES: Nc1nc(NCCOc2cccc(Cl)c2Cl)nc(NCCc2c[nH]c3ccccc23)n1
Standard InChI: InChI=1S/C21H21Cl2N7O/c22-15-5-3-7-17(18(15)23)31-11-10-26-21-29-19(24)28-20(30-21)25-9-8-13-12-27-16-6-2-1-4-14(13)16/h1-7,12,27H,8-11H2,(H4,24,25,26,28,29,30)
Standard InChI Key: XEZKYOPQXMSHAV-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 458.35 | Molecular Weight (Monoisotopic): 457.1185 | AlogP: 4.39 | #Rotatable Bonds: 9 |
Polar Surface Area: 113.77 | Molecular Species: BASE | HBA: 7 | HBD: 4 |
#RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 9.20 | CX LogP: 4.97 | CX LogD: 3.39 |
Aromatic Rings: 4 | Heavy Atoms: 31 | QED Weighted: 0.28 | Np Likeness Score: -1.06 |
1. Kułaga D, Drabczyk AK, Satała G, Latacz G, Rózga K, Plażuk D, Jaśkowska J.. (2022) Design and synthesis of new potent 5-HT7 receptor ligands as a candidate for the treatment of central nervous system diseases., 227 [PMID:34710746] [10.1016/j.ejmech.2021.113931] |
Source(1):